Brief: Clene Says Significant Long-Term Survival Improvement From CNM-Au8 Treatment In Healey ALS Platform Trial Compared To Pro-Act Historical Controls
25/09/2023 12:06
Sept 25 (Reuters) - Clene Inc. CLNN.O :
* CLENE- SIGNIFICANT LONG-TERM SURVIVAL IMPROVEMENT FROM
CNM-AU8
TREATMENT IN HEALEY ALS PLATFORM TRIAL COMPARED TO PRO-ACT
HISTORICAL CONTROLS
Further company coverage: CLNN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clene
See all newsClene Inc reports results for the quarter ended June 30 - Earnings Summary
Clene Q2 net loss widens on higher other expenses
Clene Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Clene Inc - Enters Second Amendment To Senior Secured Convertible Notes - SEC Filing
Clene Q1 loss widens on warrant liability issuance costs